H. W. Frijlink

发表

Dry powder inhalation: past, present and future

H. Frijlink, A. D. de Boer, P. Hagedoorn, 2017, Expert opinion on drug delivery.

The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer™ family.

A. D. de Boer, P. Hagedoorn, O. Akkerman, 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing.

H. Frijlink, M. Damm, H. W. Frijlink, 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers

H. Kerstjens, M. Sturkenboom, P. Hagedoorn, 2020, medRxiv.

Dry powder inhalation of colistin sulphomethate in healthy volunteers: A pilot study.

A. D. de Boer, D. Touw, H. Heijerman, 2007, International journal of pharmaceutics.

Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study.

H. Frijlink, A. D. de Boer, D. Touw, 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study.

D. Touw, H. Heijerman, H. W. Frijlink, 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Equivalence testing of salbutamol dry powder inhalers: in vitro impaction results versus in vivo efficacy.

D. Barends, P. Zanen, A. D. de Boer, 2002, International journal of pharmaceutics.

Marked Endotheliotropism of Highly Pathogenic Avian Influenza Virus H5N1 following Intestinal Inoculation in Cats

A. C. Eissens, L. Reperant, T. Kuiken, 2011, Journal of Virology.

Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.

H. Frijlink, A. D. de Boer, P. Hagedoorn, 2006, International journal of pharmaceutics.

Design and application of a new modular adapter for laser diffraction characterisation of inhalation aerosols

W. Witt, P. Hagedoorn, M. Schaller, 2005 .

Design and application of a new modular adapter for laser diffraction characterization of inhalation aerosols.

W. Witt, A. D. de Boer, P. Hagedoorn, 2002, International journal of pharmaceutics.

Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer.

H. Frijlink, A. D. de Boer, P. Hagedoorn, 1999, International journal of pharmaceutics.

A review of the technical aspects of drug nebulization

H. Frijlink, A. D. de Boer, H. Heijerman, 2000, Pharmacy World & Science.

In vitro evaluation of the DP-4M PennCentury insufflator.

A. D. de Boer, P. Hagedoorn, M. Hoppentocht, 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Air classifier technology (ACT) in dry powder inhalation Part 3. Design and development of an air classifier family for the Novolizer multi-dose dry powder inhaler.

H. Frijlink, A. D. de Boer, P. Hagedoorn, 2006, International journal of pharmaceutics.

Chapter 9 Air classifier technology ( ACT ) in dry powder inhalation Part 3 : Design and development of an air classifier family for the Novolizer ® multi-dose dry powder inhaler

P. Hagedoorn, H. W. Frijlink, D. Gjaltema, 2005 .

Development of a zero-order sustained-release tablet containing mesalazine and budesonide intended to treat the distal gastrointestinal tract in inflammatory bowel disease.

A. C. Eissens, J. Kosterink, H. W. Frijlink, 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients.

A. Vinks, A. D. de Boer, D. Touw, 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Comparative in vitro performance evaluation of the Novopulmon 200 Novolizer and Budesonid-ratiopharm Jethaler: two novel budesonide dry powder inhalers.

A. D. de Boer, P. Hagedoorn, H. W. Frijlink, 2004, Die Pharmazie.

Air classifier technology (ACT) in dry powder inhalation. Part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures.

H. Frijlink, A. D. de Boer, P. Hagedoorn, 2003, International journal of pharmaceutics.

Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle.

A. D. de Boer, P. Hagedoorn, H. Heijerman, 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

The effect of budesonide particle mass on drug particle detachment from carrier crystals in adhesive mixtures during inhalation.

A. D. de Boer, B. Dickhoff, H. W. Frijlink, 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Design and in vitro performance of a disposable inhaler (Twincer) with multiple air classifier technology for high powder doses

P. Hagedoorn, H. Heijerman, H. W. Frijlink, 2005 .

The rate of drug particle detachment from carrier crystals in an air classifier based dry powder inhaler

P. Hagedoorn, H. W. Frijlink, D. Gjaltema, 2005 .

The choice of a compressor for the aerosolisation of tobramycin (TOBI) with the PARI LC PLUS reusable nebuliser.

A. D. de Boer, P. Hagedoorn, H. W. Frijlink, 2003, International journal of pharmaceutics.

A critical evaluation of the relevant parameters for drug redispersion from adhesive mixtures during inhalation.

H. Frijlink, A. D. de Boer, B. Dickhoff, 2005, International journal of pharmaceutics.

Air classifier technology (ACT) in dry powder inhalation. Part 2. The effect of lactose carrier surface properties on the drug-to-carrier interaction in adhesive mixtures for inhalation.

H. Frijlink, A. D. de Boer, P. Hagedoorn, 2003, International journal of pharmaceutics.

Inhalation of tobramycin in cystic fibrosis. Part 2: optimization of the tobramycin solution for a jet and an ultrasonic nebulizer.

A. D. de Boer, P. Hagedoorn, H. Heijerman, 1999, International journal of pharmaceutics.

Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique.

P Hagedoorn, A H de Boer, H. Frijlink, 2002, International journal of pharmaceutics.

Colistin dry powder inhalation with the Twincer™: An effective and more patient friendly alternative to nebulization

J. Vonk, H. Frijlink, G. Koppelman, 2020, PloS one.

Accepting higher morbidity in exchange for sacrificing fewer animals in studies developing novel infection-control strategies.

V. Rotello, W. Hinrichs, D. Grainger, 2019, Biomaterials.

Learning from Parkinson's patients: usability of the Cyclops dry powder inhaler.

T. van Laar, P. Hagedoorn, H. W. Frijlink, 2019, International journal of pharmaceutics.

Marked Endotheliotropism of Highly Pathogenic Avian Influenza Virus H5N1 following Intestinal Inoculation in Cats

A. C. Eissens, L. Reperant, T. Kuiken, 2011, Journal of Virology.